Lead Product(s): Adagrasib
Therapeutic Area: Oncology Product Name: MRTX849
Highest Development Status: Phase III Product Type: Small molecule
Partner/Sponsor/Collaborator: Mirati Therapeutics
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration May 25, 2021
QIAGEN is developing a tissue-based companion diagnostic to identify patients with cancers that have a KRASG12C mutation who may benefit from treatment with adagrasib, Mirati’s investigational, highly selective and potent oral small molecule inhibitor of KRASG12C.